// App-Quantinova.ai

: Direct Oral Anticoagulants As Secondary Prophylaxis in Classical Myeloproliferative Neoplasms

Researchers

Presenter

  • Jacki Day

Principal Investigators

  • Allison Deal

  • Yue Wang

  • Benyam Muluneh

  • Daniel Crona

  • Brandi Reeves

Medical Centers

  • Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Department of Pharmacy, University of North Carolina Medical Center, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

  • Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, Chapel Hill, NC

  • Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina, Chapel Hill, NC

  • Hematology / Oncology, Univeristy of North Carolina, Chapel Hill, NC

  • Lineberger Comprehensive Cancer Center at the University of North Carolina, Chapel Hill, NC

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Myeloid neoplasms

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Warfarin

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved